A new trading day began on Tuesday, with Cullinan Therapeutics Inc (NASDAQ: CGEM) stock price up 3.29% from the previous day of trading, before settling in for the closing price of $18.26. CGEM’s price has ranged from $7.64 to $30.19 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -20.00% over the past five years. Meanwhile, its annual earnings per share averaged 12.53%. With a float of $38.57 million, this company’s outstanding shares have now reached $42.90 million.
Let’s look at the performance matrix of the company that is accounted for 85 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cullinan Therapeutics Inc is 33.47%, while institutional ownership is 77.55%. The most recent insider transaction that took place on Jul 05 ’24, was worth 130,640. In this transaction Chief Scientific Officer of this company sold 8,000 shares at a rate of $16.33, taking the stock ownership to the 123,942 shares. Before that another transaction happened on May 06 ’24, when Company’s Chief Scientific Officer sold 58,000 for $28.07, making the entire transaction worth $1,628,159. This insider now owns 129,582 shares in total.
Cullinan Therapeutics Inc (CGEM) Performance Highlights and Predictions
In its latest quarterly report, released on 6/30/2024, the company reported earnings of -0.91 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.53% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Here are Cullinan Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 28.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.26 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Cullinan Therapeutics Inc (NASDAQ: CGEM) saw its 5-day average volume 0.45 million, a negative change from its year-to-date volume of 0.7 million. As of the previous 9 days, the stock’s Stochastic %D was 85.76%. Additionally, its Average True Range was 1.06.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 24.42%, which indicates a significant decrease from 93.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.54% in the past 14 days, which was lower than the 81.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.63, while its 200-day Moving Average is $16.60. Nevertheless, the first resistance level for the watch stands at $19.29 in the near term. At $19.72, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.38. If the price goes on to break the first support level at $18.20, it is likely to go to the next support level at $17.55. Assuming the price breaks the second support level, the third support level stands at $17.12.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
With a market capitalization of 1.09 billion, the company has a total of 57,634K Shares Outstanding. Currently, annual sales are 0 K while annual income is -153,160 K. The company’s previous quarter sales were 0 K while its latest quarter income was -42,030 K.
